Abstracts Archive - Page 1302 of 2425 - ACR Meeting Abstracts

Abstract Number: 1447 • 2017 ACR/ARHP Annual Meeting
Smoking Reduces Efficacy of Biologics Differently By Target Cytokines in Rheumatoid Arthritis
Kentaro Kuzuya¹, Yukihiko Saeki², Jun Hashimoto³, Shirou Oshima⁴, Masato Matsushita⁵, Souichirou Tuji⁴, Yoshinori Harada⁶, Maiko Yoshimura⁶, Satoru Teshigawara⁶ and Hidetoshi Matsuoka⁴, ¹Rheumatology and Allegology, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ²Dept of Clinical research, Osaka-Minami Medical Ctr, Osaka, Japan, ³Rheumatology/Orthopaedics, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ⁴Division of Rheumatology, Osaka-Minami Medical Ctr, Osaka, Japan, ⁵Rheumatology, Osaka-Minami Medical Ctr, Osaka, Japan, ⁶Osaka-Minami Medical Ctr, Kawachinagano, Japan
Background/Purpose: Biologiccs (Bio) have shown outstanding efficacy and became one of the most effective drugs in the treatment of RA. However, several issues remain, including…
Abstract Number: 1448 • 2017 ACR/ARHP Annual Meeting
Prospective, Intervention, Multicenter, Non-Inferiority Study of Utility of Therapeutic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases
Catalina Gómez Arango¹, Maria Luz Garcia Vivar², Eduardo Úcar Angulo¹, Iñigo Gorostiza³, Clara Eugenia Perez², Juan Ramon De Dios⁴, Belen Alvarez⁵, Ana Ruibal Escribano⁶, Claudia Stoye⁵, Margarida Vasques⁵, Joaquin Belzunegui Otano⁷, Antonio Escobar³, Ziortza Trancho⁸, Ainhoa Ruiz del Agua⁹, Lorena Del Rio⁹, Cristina Jorquera¹⁰, Antonio Martínez⁹ and Daniel Nagore⁹, ¹Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ²RHEUMATOLOGY, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ³Research Unit, Basurto Univeristy Hospital, Bilbao, Spain, ⁴Rheumatology Department. Hospital Universitario de Araba, Vitoria, Spain, ⁵Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁶Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ⁷Donostia University Hospital, San Sebastian, Spain, ⁸Unidad de Investigación, Hospital Universitario de Basurto, Bilbao, Spain, ⁹R&D, Progenika-Grifols, Derio, Spain, ¹⁰Hospital Universitario de Basurto, Bilbao, Spain
Background/Purpose: Adalimumab (ADL) tapering based on clinical assessment is an usual practice, especially in patients in remission. The objective of INGEBIO was to analyze how…
Abstract Number: 1449 • 2017 ACR/ARHP Annual Meeting
Development of a Predictive Score of Successful TNF Inhibitor Tapering in Patients with Rheumatoid Arthritis Remission
Clothilde Barral¹, David Hajage², Bruno Fautrel³, Pierre Lafforgue¹, Florence Tubach² and Thao Pham¹, ¹Rheumatology, APHM, Aix Marseille Univ, Marseille, France, ²APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, ³Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France
Background/Purpose: Tapering trials confirmed the feasibility of TNF inhibitors (TNFi) tapering for a relevant proportion of patients in remission and/or low disease activity. However, there…
Abstract Number: 1450 • 2017 ACR/ARHP Annual Meeting
Influence of Immunogenicity to the First Anti-TNF Therapy on Response to the Second Biologic Agent in RA Patients
Patricia Bogas¹, Chamaida Plasencia-Rodriguez¹, Alejandro Balsa¹, Dora Pascual-Salcedo², Gema Bonilla¹, Enrique Moral Coro¹, Carolina Tornero¹, Laura Nuño¹, Diana Peiteado³, Ana Martínez⁴ and Borja Hernández¹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Immuno-Rheumatology Research group, La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Immuno-Rheumatology research group, La Paz University Hospital, MADRID, Spain
Background/Purpose: There is currently no consensus on selecting a therapeutic target in patients (pts) non-responsive to their first TNF inhibitors (TNFi). The development of anti-drug…
Abstract Number: 1451 • 2017 ACR/ARHP Annual Meeting
Starting of Biological Dmards May be Postponed in RA Patients with Multimorbidity: Single Centre Real Life Results
Berkan Armagan¹, Alper Sari¹, Abdulsamet Erden¹, Levent Kilic¹, Efe Cem Erdat², Omer Karadag³, Ali Akdogan¹, Sule Apras Bilgen³, Ihsan Ertenli³, Sedat Kiraz¹ and Umut Kalyoncu^1,3, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: RA is a burdensome for most of the patients, comorbidities usually provide additional disadvantags the course of RA. The possible effects of comorbidities on…
Abstract Number: 1452 • 2017 ACR/ARHP Annual Meeting
Handling of Missing Data, Protocol Violation and Performance of Intention-to-Treat Analysis in the Randomized Controlled Trials of Drug Therapy of Rheumatoid Arthritis
Fawad Aslam¹, Karina Torralba² and Nasim A. Khan³, ¹Rheumatology, Mayo Clinic, Scottsdale, AZ, ²Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA, ³Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR
Background/Purpose: Intention-to-treat (ITT) method is recommended to analyze Randomized Controlled Trials (RCTs). It requires analyzing all participants per the assigned intervention group at randomization to…
Abstract Number: 1453 • 2017 ACR/ARHP Annual Meeting
Impact of Biological and Targeted Synthetic Dmards on Work in Patients with Chronic Inflammatory Arthritides : A Meta Analysis of Randomized Controlled Trials and Controlled Cohorts
Charlotte Traverson¹, Amandine Tubery¹, Charlotte Hua², Françoise Barchechath-Flaisler¹, Cédric Lukas³, Bernard Combe², Jacques Morel² and Cécile Gaujoux-Viala⁴, ¹Rheumatology, Nîmes University Hospital, Nîmes, France, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France
Background/Purpose: The addition of biological (b) and new targeted synthetic (ts) DMARDs agents in chronic inflammatory arthritides (CIAs) therapeutic strategies has improved the possibility of…
Abstract Number: 1454 • 2017 ACR/ARHP Annual Meeting
Association of Poor Prognostic Factors with Medication Persistence Among Adult RA Patients within a Community of Rheumatology Clinics
Damemarie Paul¹, Laura McDonald², Aarti Rao³, Ruthwik Anupindi⁴ and Keith Knapp^5,6, ¹HEOR, Bristol Myers Squibb, Lawrence Township, NJ, ²CORDS, Bristol Myers Squibb, Uxbridge, United Kingdom, ³Analytics, Mu-Sigma, Bengaluru, India, ⁴Analytics, Mu-Sigma, Lawrence Township, NJ, ⁵Arthritis Northwest PLLC., Spokane, WA, ⁶Discus Analytics LLC., Spokane, WA
Background/Purpose: A fixed treatment paradigm often exists for Rheumatoid Arthritis(RA) patient(pts)1. However, RA is a heterogeneous disease and differences in pts’ serostatus affect disease progression.…
Abstract Number: 1455 • 2017 ACR/ARHP Annual Meeting
Investigation of Poor Prognostic Factors Among Rheumatoid Arthritis Patients in Turkbio Registry
Nevsun Inanc¹, Zeynep Erturk¹, Gulsen Ozen¹, Ediz Dalkilic², Suleyman Serdar Koca³, Gerçek Can⁴, Ahmet Karatas⁵, Yavuz Pehlivan⁶, Ayten Yazici⁷, Ayse Cefle⁷, Servet Akar⁸, Soner Senel⁹, Burak Oz³, Nurullah Akkoc¹⁰, Haner Direskeneli¹ and Fatos Onen¹¹, ¹Rheumatology, Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ³Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ⁴Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁵Department of Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ⁶Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ⁷Rheumatology, Kocaeli University, School of Medicine, Rheumatology, Kocaeli, Turkey, ⁸Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁹Rheumatology, Kayseri Erciyes University, School of Medicine, Rheumatology, Kayseri, Turkey, ¹⁰Rheumatology, Private Practice, Rheumatology, İzmir, Turkey, ¹¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
Background/Purpose: TURKBIO is the Turkish version of Danish DANBIO rheumatologic database which has been established in 2011.In 2016,the EULAR RA management guideline recommended assessment of…
Abstract Number: 1456 • 2017 ACR/ARHP Annual Meeting
Synergistic Reversal of Arthritis By Synoviocyte-Targeted Therapy and TNF Immunomodulation
Christian Secchi^1,2,3, Karen M. Doody², Mattias N. D. Svensson^2,4, Frances Humby⁵, Rebecca Hands⁵, Eugenio Santelli^1,2, Cristiano Sacchetti^2,6, Kuninobu Wakabayashi⁷, Dennis J. Wu⁸, Ardita Aliko⁹, Piotr Mydel^9,10, Tsuyoshi Kasama⁷, David L. Boyle¹¹, Francesco Galimi¹², Michel L. Tremblay¹³, Gary S. Firestein⁶, Costantino Pitzalis⁵, Stephanie Standford^8,14 and Nunzio Bottini^2,4, ¹Medicine, University of California San Diego, San Diego, CA, ²Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ³Medicine, National Institute of Biostructures and Biosystems, University of Sassari Medical School, Sassari, Italy, ⁴Department of Medicine, University of California San Diego, La Jolla, CA, ⁵Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁶Medicine, University of California San Diego, La Jolla, CA, ⁷Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ⁸University of California San Diego, San Diego, CA, ⁹University of Bergen, Bergen, Norway, ¹⁰Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, ¹¹University of California San Diego, La Jolla, CA, ¹²National Institute of Biostructures and Biosystems, University of Sassari Medical School, Sassari, Italy, ¹³Goodman Cancer Centre, McGill University, Montréal, QC, Canada, ¹⁴La Jolla Institute for Allergy and Immunology, La Jolla, CA
Background/Purpose: Despite the availability of immunosuppressive disease-modifying anti-rheumatic agents (DMARDs), many rheumatoid arthritis (RA) patients still fail to achieve remission. Fibroblast-like synoviocytes (FLS) are non-immunological…
Abstract Number: 1457 • 2017 ACR/ARHP Annual Meeting
Perioperative Management of Methotrexate and Tumor Necrosis Factor Inhibitor Combination Therapy in Rheumatoid Arthritis Patients
Hsin-Hsuan Juo^1,2 and Bernard Ng^1,3, ¹rheumatology, University of Washington, seattle, WA, ²rheumatology, VA Puget Sound Health Care System, seattle, WA, ³Rheumatology, VA Puget Sound Health Care System, seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher frequency of requiring surgical procedures and worse surgical outcome. However, literature regarding post-surgical infectious outcome associated with…
Abstract Number: 1458 • 2017 ACR/ARHP Annual Meeting
Correlation of Multi-Biomarker Disease Activity Score with Clinical Disease Activity Measures for the JAK1-Selective Inhibitor Filgotinib As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients
Mark C. Genovese¹, René Galien², Yang Pan³, Annegret Van der Aa⁴, Corinne Jamoul⁴, Pille Harrison⁴, Chantal Tasset⁴, Lovely Goyal³, Wanying Li³ and Jacqueline Tarrant³, ¹Stanford University Medical Center, Palo Alto, CA, ²Galapagos SASU, Romainville, France, ³Gilead Sciences, Foster City, CA, ⁴Galapagos NV, Mechelen, Belgium
Background/Purpose: The JAK1 selective inhibitor filgotinib (GLPG0634, GS-6034) was efficacious as both add-on to methotrexate (MTX) and monotherapy in two 24-week phase 2B studies in…
Abstract Number: 1459 • 2017 ACR/ARHP Annual Meeting
Lack of Drug-Drug Interaction between Filgotinib, a JAK-1 Selective Inhibitor, and a Representative Hormonal Contraceptive Medication, Levonorgestrel/Ethinyl Estradiol
Rebecca Begley¹, Kacey Anderson², Timothy R. Watkins¹, Jing Shen¹, Hao Zheng¹, Eugene Vass¹, Ann Qin², Brian P. Kearney² and Yan Xin², ¹Gilead Sciences, Inc., Foster City, CA, ²Clinical Pharmacology, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib is a potent and selective JAK1 inhibitor in clinical development for treatment of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel diseases. Filgotinib…
Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting
Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice
Takaaki Komiya¹, Kaoru Minegishi-Takase², Natsuki Sakurai¹, Yuichiro Sato¹, Hideto Nagai³, Naoki Hamada³, Yumiko Sugiyama³, Naomi Tsuchida¹, Yutaro Soejima³, Yosuke Kunishita³, Hiroto Nakano³, Daiga Kishimoto³, Koji Kobayashi², Reikou Kamiyama³, Ryusuke Yoshimi³, Yukiko Asami³, Yohei Kirino³, Shigeru Ohno⁴ and Hideaki Nakajima³, ¹Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ³Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…
Abstract Number: 1461 • 2017 ACR/ARHP Annual Meeting
The Relationship between Serum IL-37 and Disease Activity in Patients with Rheumatoid Arthritis: Post-Hoc Analysis of Planetra Study
Seoung Wan Nam¹, Hyuk Hee Kwon², Ga-Young Ahn³, Min Jung Kim² and Dae-Hyun Yoo¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
The relationship between serum IL-37 and disease activity in patients with rheumatoid arthritis: post-hoc analysis of PLANETRA study. Background/Purpose: Rheumatoid Arthritis (RA) is a chronic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].